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ABSTRACT
Introduction: Boerhaavia diffusa Linn. (Family: Nyctaginaceae) is a widely used plant in India 
and Brazil as a traditional medicine for treatment of urolithiasis and other urinary disorders. 
Objectives: The aim of this study was to evaluate the antiurolithic activity of Boerhaavia diffusa 
root aqueous extract (BDE) as prophylaxis for renal stones.
Methods: In vitro calcium oxalate (CaOx) crystallization inhibitory effect of BDE was determined 
by measuring change in turbidity at 620nm on addition of sodium oxalate in the synthetic urine. In 
a rat model of urolithiasis, induced by adding 0.75% ethylene glycol (EG) in drinking water and 
effect of simultaneous treatment of BDE (100-200 mg/kg) was observed for 28 days.
Results: BDE inhibited CaOx nucleation, aggregation and crystal formation in the synthetic urine 
in vitro on addition of NaOx. The lithogenic treatment caused polyuria, weight loss, hyperoxaluria 
and impairment of renal function which was prevented by BDE. Hyperoxaluria and CaOx crystal 
deposition in the renal tubules caused by EG intake was prevented by BDE treatment. 
Conclusion: This study indicates that the antiurolithic activity of Boerhaavia diffusa extract 
possibly mediated through inhibition of CaOx crystallization, diuresis and hypo-oxaluria may 
justify its prophylactic use in urolithiasis.
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INTRODUCTION                                                    
Urolithiasis (the formation of kidney, 
ureteric or bladder stones) poses a severe 
health problem in mankind1. It affects 4-8% 
of the population in the UK, 15% in the US, 
20% in Gulf countries and 11% in India. 
Epidemiological data suggest that 60-80% 
of stones are composed of calcium oxalate 
(CaOx). Unless prophylactic measures are 
taken, the stone recurrence rate is about 40% 
in 3 years, 75% in 10 years and during the 
next 25 years every patient has at least one 
more stone recurrence1, 2. 
Treatment procedures for renal stones 
such as surgical removal, percutaneous 
techniques and extracorporeal shock wave 
lithotripsy (ESWL) are prohibitively costly 
and with these procedures recurrence is quite 
common3. Complications include residual 
stone fragments, compromised renal function, 
acute renal injury and urinary tract infection4. 
However, herbal remedies have been found 
to be effective in reducing the recurrence rate 
of renal stones3. In India, in the Ayurvedic 
system of medicine, Pashanabheda (Pashana-
stone; Bheda-break) is the Sanskrit term 
used for a group of plants with diuretic 
and antiurolithic activities. In Indian folk 
medicine many plants have been used to treat 
kidney stones, including Boerhaavia diffusa.
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pressure. A thick and dark brown material 
(52 gm), the crude Boerhaavia diffusa extract 
(BDE) was obtained, the approximate yield 
was 10.4%. 
Animals 
Twenty four inbred male Wistar rats (180-
200 gm body weight) were used. Animals 
were procured from the Institutional Ani-
mal House of Birla Institute of Technology, 
Mesra. All animals were kept in polyacrylic 
cages and maintained under standard hou-
sing conditions (room temperature 24-27°C 
and humidity 60-65% with 12:12 light: dark 
cycles).  Food was provided in the form of 
dry pellets and water ad libitum. The ani-
mals were allowed to get acclimatized to the 
laboratory conditions for 7 days before the 
commencement of the experiment. All ex-
periments involving animals complied with 
the ethical standards of animal handling and 
were approved by the Institutional Animal 
Ethics Committee and CPCSEA India.
In vitro study: CaOx crystallization assay 
in synthetic urine
The effect of BDE on CaOx crystallization 
was determined by the time course 
measurement of turbidity changes due to 
crystal nucleation and aggregation in the 
synthetic urine on addition of sodium oxalate 
(NaOx). The precipitation of CaOx at 37°C 
and pH 6.8 was studied by the measurement 
of turbidity at 620 nm. A spectrophotometer 
UV/Vis (Shimadzu 1700) was employed to 
measure the turbidity of the formation of 
CaOx. Aliquots of 2 ml of synthetic urine 
were pipetted into test tubes and 0.2 ml 
of BDE of various strength (5%, 10% and 
20%) were added and incubated at 37°C for 
30 minutes. 0.2ml distilled water instead of 
BDE was used as control. Finally 1 ml of 4 
mM NaOx was added and absorbance was 
measured at 620 nm. Tests were performed 
in triplicate8.
Optical density (OD) was measured over 
10 min and the percentage of inhibition 
produced by the additions was calculated by 
% inhibition = {1-(St / Sc)} X 100.  Where; 
St: slope of graph in the presence of BDE, Sc: 
slope of graph in control experiments9.
Boerhaavia diffusa Linn., commonly 
known as Punarnava in India and Erva tostão 
in Brazil is a herbaceous plant of the family 
Nyctaginaceae. The roots of Boerhaavia dif-
fusa have held an important place in herbal 
medicine in both Brazil and India since an-
cient time. It is used to treat gallbladder 
stones, liver disorders (jaundice and hepa-
titis), urinary tract and renal disorders in-
cluding kidney stones5,6. Root decoctions of 
this plant are used to treat kidney stones in 
many regions of India7.  The plant is also in-
cluded in the Indian Pharmacopoeia 2006 as 
a diuretic agent. The herbal extract of Boer-
haavia diffusa inhibits the growth of struvite 
crystals in vitro3, suggesting that it may have 
antiurolithic activity. Boerhaavia diffusa is 
also an important ingredient of a polyherbal 
formulation Cystone (Himalaya Health Care 
Pvt. Ltd) widely used for the treatment of 
renal stone disease. However, no scientific 
study has been conducted  to justify the use 
of plants in urolithiasis. 
The aim of this study was to establish the 
scientific validity for the prophylactic role of 
Boerhaavia diffusa root extracts in urolithia-
sis, using an ethylene glycol induced hyper-
oxaluria model in rats.
MATERIAL AND METHODS                                     
Plant material and extraction 
Boerhaavia diffusa was collected from 
Birla Institute of Technology, Mesra campus 
Ranchi, India during August. A sample of the 
plant material was submitted to the herbarium 
of the Botanical Survey of India in Kolkata. 
The plant was authenticated as “Boerhaavia 
diffusa Linn. variety red”.
The dried roots of the plant were cleaned 
of dirt and ground to powder, using a 
commercial mill. Approximately 500 gm 
of the plant powder was soaked in 2.5 liter 
water at room temperature for 24 hours with 
occasional shaking. It was filtered through a 
single layer of muslin cloth and the final filtrate 
was collected by passing it through a What 
man grade 1 filter paper in a Buchner funnel 
under vacuum. The filtrate was evaporated to 
dryness on a rotary evaporator under reduced 
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In vivo study: Antiurolithic activity 
The rat model of ethylene glycol (EG) 
induced hyperoxaluria described by Atmani 
et al 200310 was used to assess antiurolithic 
activity in vivo. Male Wistar rats weighing 
180-200 gm were housed in metabolic cages 
three days prior to the start of the experiment 
The animals were divided into four groups 
comprising six animals each. EG was added 
to their drinking water for 28 days to induce 
a chronic low grade hyperoxaluria and 
precipitate CaOx deposition in the kidneys. 
Simultaneously, BDE was administered to 
the treatment group. One tenth of LD50 was 
selected as the higher dose and half of this 
was selected as the lower dose. Group 1 was 
used as normal control and was given water 
only; Group 2 was given 0.75% v/v EG in 
drinking water and served as the untreated 
nephrolithiasis group. Group 3 was given 
0.75% v/v EG in drinking water plus 100 
mg/kg p.o. of BDE and served as the treated 
nephrolithiasis group. Group 4 was given 
0.75% v/v EG in drinking water plus 200 
mg/kg p.o. of BDE and served as the treated 
nephrolithiasis group. During the study of 28 
days various urine and serum biochemical 
parameters as well as histopathology of 
the kidneys were assessed for antiurolithic 
activity.
General observations
During the study period body weight, 
water intake and animal health was observed 
regularly, so that stressed and unhealthy 
animal were excluded from study11.
Urine analysis
All animals were kept in individual 
metabolic cages and 24 hour urine samples 
were collected daily. Animals had free access 
to drinking water during the urine collection 
period. Volume and pH were measured 
immediately after collection. A drop of 
concentrated hydrochloric acid was added 
to the urine before being stored at 4°C12. 
Urine was analyzed for calcium, phosphate 
and oxalate content using commercial kits. A 
quantitative microscopic crystalluria analysis 
was performed by counting the number of 
crystals. Twenty-four hour urine samples 
were first mixed well and then aliquots were 
withdrawn and placed on malassez cell and 
examined microscopically (Leica DME)13. 
The number of crystals was expressed in 
crystals/mm3  
Serum analysis
After the experimental period, blood was 
collected by cardiac puncture under anesthetic 
conditions and the animals were sacrificed. 
Serum was separated by centrifugation 
at 10.000×g for 10 min and analyzed for 
creatinine and blood urea nitrogen12.
Kidney homogenate analysis
The abdomen incised to remove both 
kidneys from each animal. Isolated kidneys 
were cleaned of extraneous tissue. Left kid-
neys were preserved in 10% neutral formalin 
for histopathological examination and right 
kidneys were dried at 80°C in a hot air oven. 
A sample of 100 mg of the dried kidney was 
boiled in 10 ml of 1N hydrochloric acid for 
30 min and homogenized. The homogenate 
was centrifuged at 2000×g for 10 min and 
the supernatant was separated14. The calcium, 
phosphate and oxalate content in kidney ho-
mogenates was determined.
Histopathological examination
The left kidneys were fixed in 10% 
formalin solution in 0.1M phosphate buffer 
saline. dehydrated in ascending grades of 
alcohol and embedded in paraffin. Sections 
of 6μm thickness were taken, stained with 
hematoxylin and eosin and examined 
histologically under a light microscope 
(Leica DME)13.
Statistical analysis
Data are expressed as mean ± standard 
error of mean (SEM). Comparisons between 
groups were made by means of one way 
analysis of variance (ANOVA) with post 
hoc Dunnett’s t-test (p<0.01 regarded as 
significant). Concentration response curves 
were analyzed by linear regression using 
Graphpad Prism 5 software.
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RESULTS                                                            
Effects on in-vitro CaOx crystallization 
The effect of BDE on various phases of 
CaOx crystallization was determined by 
time course measurement of turbidity in 
the urine. Fig. 1 shows an initial detectable 
increase in the turbidity after induction of 
the crystallization with NaOx. In the control 
experiment it shows the initial steep rise in 
turbidity (nucleation phase) and on attaining 
its maximum it was followed by a decrease in 
turbidity (aggregation phase). BDE decreased 
the slope of turbidity in a concentration 
dependent manner as shown in Fig. 1. 
Crystallization was inhibited by19.7%, 33. 
8% and 57.2% at 5%, 10% and 20% BDE, 
respectively.
Effect observed in animal model
Body weight, water intake, urine volume 
and pH before the start of experiment were 
not significantly different among the study 
groups. The parameters recorded during 
the experimental period are shown in 
Table 1. The mean weight of the untreated 
group decreased significantly (p<0.01) 
compared to the normal and treated groups. 
However, the BDE treated groups did not 
show any significant change in body weight. 
Water intake significantly (p<0.01) increased 
in all groups compared to the control group.
EG treatment reduced the urine pH in 
the untreated group compared to that of the 
control group, although not significantly. 
Co-treatment with BDE increased urine 
volume (p<0.01) in a dose-dependent 
manner, although these parameters remained 
higher than those of the untreated animals 
even at 100 mg/kg (p<0.05). EG treatment 
also increased oxalate excretion (p<0.01) 
in the untreated animals. BDE at 100 and 
200 mg/kg prevented the change in urinary 
oxalate (p<0.05 and p<0.01, respectively). 
Other changes in urine composition induced 
by the lithogenic treatment such as calcium 
and phosphate excretion were not statistically 
significant (Table 1).
Microscopy revealed that the urine of 
hyperoxaluric rats contained numerous CaOx 
monohydrate (COM) crystals (dumbbell-
shaped) and CaOx dihydrate (COD) crystals 
(bipyramidal shaped) whereas the urine of 
control rats was devoid of crystals (Fig. 2a 
and 2b).  At 100 and 200 mg/kg BDE reduced 
the crystal size with significant decrease 
in number (p<0.01) (Fig. 2c and 2d) and 
(Table 1).
Lithogenic treatment impaired renal 
function in the untreated rats as evident from 
raised BUN and serum creatinine (p<0.01), 
which was dose-dependently prevented in 
the animals receiving BDE (Table 1). Serum 
oxalate increased in untreated rats (p<0.01). 
However, serum calcium and phosphate l did 
not show significant changes.
The kidneys were larger and heavier in the 
untreated group, but not in the BDE treated 
groups, compared with the control group (p < 
0.01). The calcium and oxalate content of the 
kidneys was significantly (p<0.01) increased 
in the untreated group, but not in the BDE 
treated groups (Table 1).
Fig. 1: Change in turbidity with time course measured by 
variation in absorbance at 620nm with and without inhibitor 
(BDE); various curves showing the percentage inhibition of 
calcium oxalate crystallyzation with BDE with respect to 
control.
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On microscopy many birefringent 
crystalline deposits were seen in all regions 
of the kidneys of all animals in the untreated 
group (Fig. 3b). In the BDE treated groups 
such deposits were comparatively small and 
rare (Fig. 3c and 3d). In untreated rats the 
renal tubules were also markedly dilated, 
with widespread necrosis of the tubular 
epithelium and deposition of birefringent 
oxalate crystals.
Other findings observed in untreated rats 
included generalized congestion and diffuse 
petechial haemorrhage in internal organs. The 
kidneys appeared swollen with pale cortex 
and dark medulla.
DISCUSSION                                                             
Kidney stone formation is a physico-
chemical process including various events 
starts with supersaturation, nucleation, 
growth, aggregation, and retention within 
renal tubules15. Different in-vitro models 
were used to study various physico-chemical 
events and simulate the urinary conditions 
by various authors16. We have evaluated 
the effect of BDE on CaOx crystallization 
kinetics by the time course measurement of 
turbidity. Since the initial events of nucleation 
occurs in the first few minutes, the graphs 
were re-plotted within the first 3-min for each 
of BDE concentration as well as for control17. 
Fig. 2: CaOx crystals in the urine of different treatment groups seen under a microscope (Leica DME) at 40×10X magnification (a) 
Untreated rats excreted numerous oval COM and pyramidal shaped COD (b) Control rats showed very few or no crystals (c & d) Treated 
rats excreted significantly reduced number of COD and few COM.
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The initial positive slope of the turbidity 
curve shows increase in number of particle 
during nucleation phase and later plateau 
(negative slope) reflects the decrease in the 
particle number, during crystal aggregation 
phase18. In this study, BDE inhibited the 
CaOx crystal nucleation and aggregation in 
a concentration dependent-manner. Ability 
of BDE to reduce the nucleation increases 
the metastable limit of oxalate in urine and 
prevents the precipitation of the CaOx crystal 
in kidney. Various physiological inhibitors 
of urolithiasis found in urine including 
citrate, glycosaminoglycans and other 
macromolecules. Citrate preferentially binds 
to calcium to form soluble salt and inhibit 
nucleation, whereas glycosaminoglycans 
and other macromolecule inhibit aggregation 
and growth by adsorbing over the surface of 
crystals19. Interference with crystal growth 
and aggregation therefore seems a possible 
therapeutic strategy for the prevention of 
recurrent stone disease. The medicinal 
plants contain chemical compounds which 
themselves possess an inhibitor effect in 
the crystallization of CaOx. Macromolecule 
of higher molecular weight of plant extract 
excerpts their action similar to natural urinary 
inhibitors and inhibits crystal aggregation and 
growth. It is reported that Boerhaavia diffusa 
have some macromolecular constituent 
(>20KD) which may attribute this property6.
Fig. 3: Histopathological examination of kidney slides of different treatment groups seen under a microscope (Leica DME) at 40×10X 
magnification (a) Control rats showing normal renal architecture (b) Kidneys of untreated rats showing polymorphic irregular crystal 
deposits inside the tubule, renal tubules were markedly dilated along with tubular epithelium necrosis;(in the figure black spots are crystal 
deposits) (c) BDE (100mg/kg) treated rats showed few crystal deposits and little dilatation of tubules (d) BDE (200mg/kg) treated rats 
showed a very few or no crystal deposits and nearly normal renal architecture.
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Renal CaOx deposition induced by EG 
in rats is frequently used by various resear-
chers to mimic the urinary stone formation 
in humans10. Oxalate is produced during me-
tabolism and excreted harmlessly in normal 
individuals. However increased concentra-
tion of oxalate in urine can be highly toxic 
because it crystallize at physiological pH to 
form CaOx20. EG metabolise to oxalate in 
body and increase its excretion in the untrea-
ted group, which was prevented by BDE in a 
dose-dependent manner. However it did not 
affect the level of calcium and phosphorus to 
a significant extent and no correlation can be 
established in excretion. Since it is accepted 
that hyperoxaluria is a far more significant 
risk factor in the pathogenesis of renal sto-
nes than hypercalciuria. Increased oxalate 
concentration is responsible for precipitation 
of CaOx crystals. BDE increased urine volu-
me in treated animals as compared to untrea-
ted animals. Increase urine volume decreases 
the saturation of the oxalate and prevents the 
precipitation of the CaOx at physiological 
pH. Diuresis also flushing out the renal sys-
tem and help in mechanical expulsion of the 
stone.
The analysis of crystalluria after 28 days 
of treatment with CaOx stone inducing 
agents showed that untreated animals 
excreted abundant and larger crystals than the 
treated animals. BDE significantly prevented 
the crystalluria associated with lithogenic 
Table 1: Various parameters recorded for assessment of antiurolithic activity during 28 days of study.




al Change in body 
weight (gm)
4.66±1.49 -7.33±5.21b 2.17±1.33 2.51±1.69
Water intake  
(ml/24hr) 10.9±0.13 14.67±0.38











Volume (ml/24hr) 6.77±0.48 12.15±0.34b 16.04±0.36b,d 24.03±1.29b,d
pH 6.8±0.03 6.4±0.06. 6.8±0.04 6.8±0.05
Crystalluria (crystals/
mm3) 4.33±1.15 125.0±7.30
 b 14.0±1.21 d 23.67±1.15 d
Calcium (mg) 0.56±0.12 0.71±0.21 0.61±0.06 0.54±0.11
Oxalate (mg) 0.46±0.06 1.85±0.61 b 0.72±0.29a,d 0.55±0.05 d








Blood urea nitrogen 
(mg/dl) 37.21±1.91 50.67±2.28
b 36.13±2.01d 27.91±1.68c,d
Creatinine (mg/dl) 0.57±0.08 0.87±0.03b 0.58±0.06c 0.36±0.09 d
Phosphorus  (mg) 2.45±0.25 2.08±0.36 2.23±0.92 2.14±0.59
Oxalate (mg) 0.29±0.03 1.82±0.46 b 0.34±0.08 d 0.36±0.37 d















Weight (gm) 0.62±0.03 1.42±0.23 b 0.74 ±0.04 0.64±0.03
Calcium (mg) 0.20±.026 1.29±0.17b 0.49±0.07d 0.30±0.08 d
Oxalate (mg) 0.27±0.05 1.58±0.15 b 0.56±0.21 d 0.24±0.05 d
Phosphorus  (mg) 2.38±0.17 2.52±0.01 2.17±0.67 2.89±0.79
Values are expressed in mean ± SEM (n=6)
a p<0.05 compared with control group b p<0.01 compared with control group;
c p<0.05 compared with untreated group d p<0.01 compared with untreated group.
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treatment. Patients with renal stone excrete 
larger and aggregated particles than the healthy 
individuals21. Change in crystal morphology 
have thereupatic virtues; first, it shows that 
substances from the plant excerpt their action 
directly or indirectly on crystal morphology. 
Second, the appearance of more COD than 
COM particles is advantageous since COM 
crystals have high adhesion affinity to renal 
epithelial cells22. 
In the present study, oxalate and calcium 
level found to be increased in untreated rats 
in kidney homogenate which is also evident 
from abundant CaOx crystal deposit in kidney. 
Increased calcium level is a factor favouring 
the nucleation and precipitation of CaOx or 
apatite (calcium phosphate) from urine and 
subsequent crystal growth23. 
CaOx crystal agglomerates, tends to 
retain in kidney by trapping in renal tubules 
and develop into renal stones. Renal stone 
deposition damages the renal tissue and 
detoriate the renal function. Treatment with 
EG leads to decrease in renal function, 
characterized by elevated level of BUN 
and serum creatinine and fall in creatinine 
clearance12, which were prevented dose-
dependent manner in the animals receiving 
a simultaneous treatment with BDE. Stone 
inducing treatment caused hypertrophy and 
extensive CaOx crystal deposition in kidneys 
of untreated rats, accompanied by oxidative 
damage as reflected from glomerular and 
tubular damage seen in the histopathological 
examination of kidney tissue (Fig. 3b). 
Renal cellular exposure to oxalate and CaOx 
crystals leads to the production of reactive 
oxygen species, development of oxidative 
stress followed by injury and inflammation. 
Renal injury and inflammation appear to play 
a significant role in stone formation21. BDE 
treatment significantly protected the kidney 
from crystal induced renal cell injury and 
other damage thus inhibited the CaOx crystal 
deposition in kidneys of rats.
CONCLUSIONS                                                      
Results of this study indicate the presence 
of antiurolithic effect of Boerhaavia diffusa 
aqueous extract against CaOx stones in 
a dose depending manner. It inhibits the 
CaOx crystal deposition and protect kidney 
from crystal induced oxidative stress 
and renal cell injury, possibly mediated 
through a combination of CaOx crystal 
inhibitory, hypoxaluric and diuretic activity. 
The study rationalizes its medicinal use for 
treatment of recurrent CaOx urolithiasis as a 
prophylactic agent.
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